Published in BMC Med on February 23, 2012
The role of autophagy in neurodegenerative disease. Nat Med (2013) 4.46
Progressive degeneration of human neural stem cells caused by pathogenic LRRK2. Nature (2012) 3.38
The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation. Biochem J (2012) 1.11
Parkinson's disease-implicated kinases in the brain; insights into disease pathogenesis. Front Mol Neurosci (2014) 1.03
Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs. PLoS One (2013) 0.99
Inhibition of LRRK2 kinase activity stimulates macroautophagy. Biochim Biophys Acta (2013) 0.98
Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348). Leukemia (2013) 0.97
Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications. Neurotherapeutics (2014) 0.94
LRRK2 kinase inhibition prevents pathological microglial phagocytosis in response to HIV-1 Tat protein. J Neuroinflammation (2012) 0.93
LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis. Exp Neurol (2014) 0.88
Contribution of GTPase activity to LRRK2-associated Parkinson disease. Small GTPases (2013) 0.87
Cellular processes associated with LRRK2 function and dysfunction. FEBS J (2015) 0.86
A Parkinson's disease gene regulatory network identifies the signaling protein RGS2 as a modulator of LRRK2 activity and neuronal toxicity. Hum Mol Genet (2014) 0.82
A Link between Autophagy and the Pathophysiology of LRRK2 in Parkinson's Disease. Parkinsons Dis (2012) 0.80
The function of orthologues of the human Parkinson's disease gene LRRK2 across species: implications for disease modelling in preclinical research. Biochem J (2016) 0.79
LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease. Biochem Soc Trans (2012) 0.78
Effects of LRRK2 Inhibitors on Nigrostriatal Dopaminergic Neurotransmission. CNS Neurosci Ther (2016) 0.75
Emerging preclinical pharmacological targets for Parkinson's disease. Oncotarget (2016) 0.75
Discovery of a Highly Selective, Brain-Penetrant Aminopyrazole LRRK2 Inhibitor. ACS Med Chem Lett (2012) 0.75
LRRK2 promotes the activation of NLRC4 inflammasome during Salmonella Typhimurium infection. J Exp Med (2017) 0.75
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron (2004) 14.35
Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron (2004) 13.99
Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet (2009) 10.34
Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet (2011) 9.10
Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet (2009) 8.11
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A (2005) 6.98
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
Parkinson's disease. Lancet (2009) 6.60
Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis (2006) 5.96
Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol (2011) 5.65
Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci (2006) 5.32
Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet (2007) 4.99
The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron (2006) 4.51
Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet (2010) 4.47
Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med (2010) 4.45
Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet (2010) 4.26
LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem J (2007) 3.89
Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J Neurochem (2008) 3.86
Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J (2008) 3.51
The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci (2010) 3.14
Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat Chem Biol (2011) 2.91
LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study. Lancet Neurol (2008) 2.85
Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro (2009) 2.85
14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochem J (2010) 2.82
Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem J (2010) 2.43
The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem Biophys Res Commun (2007) 2.42
Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J Neurochem (2007) 2.40
Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nat Neurosci (2009) 2.35
It takes two to tango: regulation of G proteins by dimerization. Nat Rev Mol Cell Biol (2009) 2.34
Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci U S A (2010) 2.34
The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Exp Cell Res (2007) 2.27
Genome-wide association study confirms BST1 and suggests a locus on 12q24 as the risk loci for Parkinson's disease in the European population. Hum Mol Genet (2010) 2.21
Investigation of leucine-rich repeat kinase 2 : enzymological properties and novel assays. FEBS J (2009) 2.14
Genome-wide association study confirms extant PD risk loci among the Dutch. Eur J Hum Genet (2011) 2.12
Translation initiator EIF4G1 mutations in familial Parkinson disease. Am J Hum Genet (2011) 2.00
Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One (2011) 1.93
Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum Mol Genet (2007) 1.72
Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2. Biochem Biophys Res Commun (2008) 1.71
An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann Neurol (2005) 1.64
LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum Mol Genet (2011) 1.52
Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities. J Mol Biol (2011) 1.42
The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylation. PLoS One (2010) 1.39
Caenorhabditits elegans LRK-1 and PINK-1 act antagonistically in stress response and neurite outgrowth. J Biol Chem (2009) 1.36
Adult neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S mice. Neurobiol Dis (2010) 1.35
Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant. J Neurochem (2011) 1.33
The WD40 domain is required for LRRK2 neurotoxicity. PLoS One (2009) 1.32
Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons. ACS Chem Biol (2011) 1.29
A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2. J Neurosci (2011) 1.25
LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting autoactivated GSK3ß. J Neurosci (2010) 1.23
Rac1 protein rescues neurite retraction caused by G2019S leucine-rich repeat kinase 2 (LRRK2). J Biol Chem (2011) 1.22
Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models. Hum Mol Genet (2011) 1.21
LRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP binding. PLoS One (2011) 1.19
Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities. Biochemistry (2010) 1.17
LRRK2 mutations in patients with Parkinson's disease from Peru and Uruguay. Parkinsonism Relat Disord (2008) 1.16
Can self-inhibitory peptides be derived from the interfaces of globular protein-protein interactions? Proteins (2010) 1.11
Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease. Mov Disord (2010) 1.10
German-Canadian family (family A) with parkinsonism, amyotrophy, and dementia - Longitudinal observations. Parkinsonism Relat Disord (1997) 1.06
Gene-environment interactions in Parkinson's disease and other forms of parkinsonism. Neurotoxicology (2010) 1.06
Clinical features of LRRK2 parkinsonism. Parkinsonism Relat Disord (2009) 1.01
The association between Parkinson's disease and melanoma. Int J Cancer (2011) 1.00
Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. Parkinsonism Relat Disord (2008) 1.00
The R1441C mutation alters the folding properties of the ROC domain of LRRK2. Biochim Biophys Acta (2009) 0.98
Founder mutation p.R1441C in the leucine-rich repeat kinase 2 gene in Belgian Parkinson's disease patients. Eur J Hum Genet (2008) 0.97
LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease. Mov Disord (2010) 0.96
Differential effects of divalent manganese and magnesium on the kinase activity of leucine-rich repeat kinase 2 (LRRK2). Biochemistry (2010) 0.95
A folding inhibitor of the HIV-1 protease. Proteins (2006) 0.94
Models for LRRK2-Linked Parkinsonism. Parkinsons Dis (2011) 0.91
Lrrk2 R1441G-related Parkinson's disease: evidence of a common founding event in the seventh century in Northern Spain. Neurogenetics (2009) 0.86
The LRRK2 R1441C mutation is more frequent than G2019S in Parkinson's disease patients from southern Italy. Mov Disord (2011) 0.83
The prevalence of the G2019S and R1441C/G/H mutations in LRRK2 in German patients with Parkinson's disease. Eur J Neurol (2008) 0.80
Identification of chemicals to inhibit the kinase activity of leucine-rich repeat kinase 2 (LRRK2), a Parkinson's disease-associated protein. Bioorg Med Chem Lett (2011) 0.79
Independent occurrence of I2020T mutation in the kinase domain of the leucine rich repeat kinase 2 gene in Japanese and German Parkinson's disease families. Neurosci Lett (2007) 0.76
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol (2010) 11.85
Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet (2009) 10.34
Abundant quantitative trait loci exist for DNA methylation and gene expression in human brain. PLoS Genet (2010) 8.74
Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis (2006) 5.96
The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci U S A (2004) 4.76
Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability. Proc Natl Acad Sci U S A (2005) 4.22
Genetics of Parkinson's disease and parkinsonism. Ann Neurol (2006) 3.60
DYT16, a novel young-onset dystonia-parkinsonism disorder: identification of a segregating mutation in the stress-response protein PRKRA. Lancet Neurol (2008) 3.03
DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy. Hum Mol Genet (2010) 3.00
Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet (2011) 2.97
Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro (2009) 2.85
The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J Biol Chem (2008) 2.77
RNA binding activity of the recessive parkinsonism protein DJ-1 supports involvement in multiple cellular pathways. Proc Natl Acad Sci U S A (2008) 2.76
Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron (2002) 2.65
Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J (2003) 2.64
Cytoplasmic Pink1 activity protects neurons from dopaminergic neurotoxin MPTP. Proc Natl Acad Sci U S A (2008) 2.64
Distinct DNA methylation changes highly correlated with chronological age in the human brain. Hum Mol Genet (2011) 2.62
An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J Neurosci (2002) 2.54
The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem Biophys Res Commun (2007) 2.42
Pink1 forms a multiprotein complex with Miro and Milton, linking Pink1 function to mitochondrial trafficking. Biochemistry (2009) 2.38
Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proc Natl Acad Sci U S A (2008) 2.36
Mitochondrial function and morphology are impaired in parkin-mutant fibroblasts. Ann Neurol (2008) 2.34
Mitochondrial alterations in PINK1 deficient cells are influenced by calcineurin-dependent dephosphorylation of dynamin-related protein 1. PLoS One (2009) 2.23
The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. Brain (2003) 2.17
A soluble α-synuclein construct forms a dynamic tetramer. Proc Natl Acad Sci U S A (2011) 2.15
L166P mutant DJ-1, causative for recessive Parkinson's disease, is degraded through the ubiquitin-proteasome system. J Biol Chem (2003) 2.12
Deletion at ITPR1 underlies ataxia in mice and spinocerebellar ataxia 15 in humans. PLoS Genet (2007) 2.09
Evidence for natural antisense transcript-mediated inhibition of microRNA function. Genome Biol (2010) 2.08
The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J Neurosci (2008) 1.86
Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiol Dis (2006) 1.83
Formation of a stabilized cysteine sulfinic acid is critical for the mitochondrial function of the parkinsonism protein DJ-1. J Biol Chem (2009) 1.71
Mutations in LRRK2/dardarin associated with Parkinson disease are more toxic than equivalent mutations in the homologous kinase LRRK1. J Neurochem (2007) 1.70
Emerging pathways in genetic Parkinson's disease: Potential role of ceramide metabolism in Lewy body disease. FEBS J (2008) 1.68
The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites. Biochem Biophys Res Commun (2009) 1.67
Evolutionary and functional relationships within the DJ1 superfamily. BMC Evol Biol (2004) 1.67
Mitochondria and dopamine: new insights into recessive parkinsonism. Neuron (2004) 1.64
Analysis of IFT74 as a candidate gene for chromosome 9p-linked ALS-FTD. BMC Neurol (2006) 1.60
MAPT expression and splicing is differentially regulated by brain region: relation to genotype and implication for tauopathies. Hum Mol Genet (2012) 1.58
Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. Proc Natl Acad Sci U S A (2014) 1.53
Mitochondrial dysfunction in a cell culture model of familial amyotrophic lateral sclerosis. Brain (2002) 1.43
Genome-wide screen identifies rs646776 near sortilin as a regulator of progranulin levels in human plasma. Am J Hum Genet (2010) 1.42
The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylation. PLoS One (2010) 1.39
Integration of GWAS SNPs and tissue specific expression profiling reveal discrete eQTLs for human traits in blood and brain. Neurobiol Dis (2012) 1.35
Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant. J Neurochem (2011) 1.33
Co-ordinate transcriptional regulation of dopamine synthesis genes by alpha-synuclein in human neuroblastoma cell lines. J Neurochem (2003) 1.32
mRNA expression, splicing and editing in the embryonic and adult mouse cerebral cortex. Nat Neurosci (2013) 1.29
MKK6 binds and regulates expression of Parkinson's disease-related protein LRRK2. J Neurochem (2010) 1.28
Membrane-associated farnesylated UCH-L1 promotes alpha-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease. Proc Natl Acad Sci U S A (2009) 1.28
Lysosomal impairment in Parkinson's disease. Mov Disord (2013) 1.27
Metabolic activity determines efficacy of macroautophagic clearance of pathological oligomeric alpha-synuclein. Am J Pathol (2009) 1.27
Resolving the polymorphism-in-probe problem is critical for correct interpretation of expression QTL studies. Nucleic Acids Res (2013) 1.25
Reelin and stk25 have opposing roles in neuronal polarization and dendritic Golgi deployment. Cell (2010) 1.25
An ENU-induced mutation in mouse glycyl-tRNA synthetase (GARS) causes peripheral sensory and motor phenotypes creating a model of Charcot-Marie-Tooth type 2D peripheral neuropathy. Dis Model Mech (2009) 1.22
Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson's disease. Hum Mol Genet (2003) 1.22
LRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP binding. PLoS One (2011) 1.19
DJ-1 regulation of mitochondrial function and autophagy through oxidative stress. Autophagy (2011) 1.19
Effects of DJ-1 mutations and polymorphisms on protein stability and subcellular localization. Brain Res Mol Brain Res (2005) 1.18
Genes and parkinsonism. Lancet Neurol (2003) 1.14
Role of LRRK2 kinase dysfunction in Parkinson disease. Expert Rev Mol Med (2011) 1.13
Amyotrophic lateral sclerosis 2-deficiency leads to neuronal degeneration in amyotrophic lateral sclerosis through altered AMPA receptor trafficking. J Neurosci (2006) 1.13
The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation. Biochem J (2012) 1.11
Biochemical characterization of highly purified leucine-rich repeat kinases 1 and 2 demonstrates formation of homodimers. PLoS One (2012) 1.09
The metalloprotease inhibitor TIMP-3 regulates amyloid precursor protein and apolipoprotein E receptor proteolysis. J Neurosci (2007) 1.09
Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies. J Neurosci (2014) 1.08
A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders. FASEB J (2004) 1.07
Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, alpha-synuclein, and tau. Bioessays (2010) 1.06
Parkinson disease-associated mutation R1441H in LRRK2 prolongs the "active state" of its GTPase domain. Proc Natl Acad Sci U S A (2014) 1.05
The role of PTEN-induced kinase 1 in mitochondrial dysfunction and dynamics. Int J Biochem Cell Biol (2009) 1.05
Modification of superoxide dismutase 1 (SOD1) properties by a GFP tag--implications for research into amyotrophic lateral sclerosis (ALS). PLoS One (2010) 1.05
Aggregation of α-synuclein in brain samples from subjects with glucocerebrosidase mutations. Mol Genet Metab (2011) 1.02
Initial assessment of the pathogenic mechanisms of the recently identified Alzheimer risk Loci. Ann Hum Genet (2013) 1.02
Age-associated miRNA alterations in skeletal muscle from rhesus monkeys reversed by caloric restriction. Aging (Albany NY) (2013) 1.00
The R1441C mutation alters the folding properties of the ROC domain of LRRK2. Biochim Biophys Acta (2009) 0.98
A direct interaction between leucine-rich repeat kinase 2 and specific β-tubulin isoforms regulates tubulin acetylation. J Biol Chem (2013) 0.97
Post-transcriptional regulation of mRNA associated with DJ-1 in sporadic Parkinson disease. Neurosci Lett (2009) 0.96
Pathogenic LRRK2 mutations do not alter gene expression in cell model systems or human brain tissue. PLoS One (2011) 0.96
The SOD1 transgene in the G93A mouse model of amyotrophic lateral sclerosis lies on distal mouse chromosome 12. Amyotroph Lateral Scler Other Motor Neuron Disord (2005) 0.95
Cell population-specific expression analysis of human cerebellum. BMC Genomics (2012) 0.95
Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications. Neurotherapeutics (2014) 0.94
Variation in tau isoform expression in different brain regions and disease states. Neurobiol Aging (2013) 0.94
Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle. Biochem J (2013) 0.94
Differential gene expression in a cell culture model of SOD1-related familial motor neurone disease. Hum Mol Genet (2002) 0.92
Mitochondrial quality control and dynamics in Parkinson's disease. Antioxid Redox Signal (2011) 0.92
A test of static and dynamic balance function in children with cochlear implants: the vestibular olympics. Arch Otolaryngol Head Neck Surg (2008) 0.92
Hexokinase activity is required for recruitment of parkin to depolarized mitochondria. Hum Mol Genet (2013) 0.90
Genetic comorbidities in Parkinson's disease. Hum Mol Genet (2013) 0.89
Expression of PINK1 mRNA in human and rodent brain and in Parkinson's disease. Brain Res (2007) 0.88
Glial cell inclusions and the pathogenesis of neurodegenerative diseases. Neuron Glia Biol (2004) 0.88
Age-associated changes in gene expression in human brain and isolated neurons. Neurobiol Aging (2012) 0.87
Tyrosinase exacerbates dopamine toxicity but is not genetically associated with Parkinson's disease. J Neurochem (2005) 0.87
ENU mutagenesis reveals a novel phenotype of reduced limb strength in mice lacking fibrillin 2. PLoS One (2010) 0.87
Alpha-synuclein overexpression increases dopamine toxicity in BE2-M17 cells. BMC Neurosci (2010) 0.85
Normal localization of deltaF323-Y328 mutant torsinA in transfected human cells. Neurosci Lett (2002) 0.85
Gene expression in the Parkinson's disease brain. Brain Res Bull (2011) 0.85
Selective loss of neurofilament expression in Cu/Zn superoxide dismutase (SOD1) linked amyotrophic lateral sclerosis. J Neurochem (2002) 0.85
Animal models for drug discovery in dystonia. Expert Opin Drug Discov (2008) 0.84